Related Experiment Videos
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration
Aiwu Zhou1, James A Huntington, Navraj S Pannu
1Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 2XY, UK.
Nature Structural Biology
|June 17, 2003
Summary
The plasma protein vitronectin stabilizes active plasminogen activator inhibitor-1 (PAI-1), impacting blood clotting and cancer. Understanding this interaction reveals therapeutic targets for thrombosis and cancer treatment.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Medicine
Background:
- The interaction between vitronectin and plasminogen activator inhibitor-1 (PAI-1) is crucial for regulating hemostasis and cell behavior.
- Active PAI-1 inhibits fibrinolysis and plays a role in angiogenesis, with elevated levels linked to thrombosis and cancer prognosis.
Purpose of the Study:
- To elucidate the structural basis of the vitronectin-PAI-1 interaction.
- To understand how vitronectin binding stabilizes active PAI-1.
- To explain PAI-1's tissue effects and identify potential therapeutic targets.
Main Methods:
- X-ray crystallography was used to determine the structure of the somatomedin B domain of vitronectin complexed with PAI-1 at 2.3 Å resolution.
Main Results:
- The crystal structure reveals how vitronectin binds to and stabilizes the active conformation of PAI-1.
- The structure explains PAI-1's role in blocking vitronectin's interaction with cell surface receptors and integrins.
- This structural insight clarifies PAI-1's contribution to thrombosis and cancer progression.
Conclusions:
- Structural understanding of the vitronectin-PAI-1 complex provides a basis for designing targeted therapies.
- Potential applications include developing agents to prevent thrombosis and treat various cancers.